BioSpace News Archive

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 15, 2022, to provide a business update and review the company’s financial results for the quarter ended June 30, 2022.

SCYNEXIS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s submission of a supplemental New Drug Application (sNDA) to expand the label of BREXAFEMME® (ibrexafungerp tablets) to include the prevention of recurrent vulvovaginal candidiasis (RVVC).

CorMedix Inc. today announced that it will report its financial results for the second quarter ended June 30, 2022, before the market open on Thursday, August 11, 2022, and will host a corporate update conference call at 8:30am Eastern Time.

Nuvectis Pharma, Inc. today announced the closing of its previously announced private placement of 1,924,689 shares of common stock.

BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity”, that supports ProLectin-M’s in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below.

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is pleased to share the Name Review Group meeting dates and respective submission deadlines, as announced by the European Medicines Agency.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA).

COUR Pharmaceuticals, today announced the publication of data, in collaboration with the Miller lab at Northwestern University, demonstrating durable tolerance using its novel platform technology in the Non-Obese Diabetic (NOD) model of type 1 diabetes (T1D), the gold standard model for autoimmunity.

Digital dentistry, including CAD/CAM dentistry, is transforming every aspect of professional oral care in dentistry to date.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022.